Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )

13.10 +0.29 (+2.26%)
Streaming Delayed Price Updated: 10:42 AM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,562
Open 13.02
Bid (Size) 13.07 (2)
Ask (Size) 13.13 (2)
Prev. Close 12.81
Today's Range 12.80 - 13.25
52wk Range 2.550 - 16.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga

Performance

YTD
+134.77%
+134.77%
1 Month
+26.94%
+26.94%
3 Month
+48.86%
+48.86%
6 Month
+72.37%
+72.37%
1 Year
+87.41%
+87.41%

More News

Read More
Looking Into ARS Pharmaceuticals's Recent Short Interest
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Via Benzinga
Exposures Product Safety
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
Via InvestorPlace
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
Via Benzinga
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
Via InvestorPlace
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
Via InvestorPlace
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
Via Benzinga
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
Via Benzinga
Exposures Product Safety
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.